|
Natalizumab
resources
|
|
|
|
|
|
DRUG INFO
Natalizumab
Drug Name:
Natalizumab
Indication: For treatment of multiple sclerosis
Pharmacology: In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain.
Mechanism Of Action: binds to the α4-subunit of � 4� 1 and � 4� 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the � 4-mediated adhesion of leukocytes to their counter-receptor(s).
Drug Category: Immunomodulatory Agents
Brand Names/Synonyms: Tysabri; anti-VLA4; anti-alpha4 integrin ; Tysabri (Antegren)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti a4 integrin antibody
Chemical Formula: Not Available
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00083
CAS Registry Number: Not Available
|
|
|
|
|
|
Natalizumab News
(When available)
Elan "add" 16 Jan 2006
New Ratings According to Goodbody Stockbrokers, the dates for result declaration imply that any substantive information regarding Tysabri is unlikely.
Biogen: FDA to rule on Tysabri Jan 10, 2006
MarketWatch ...that they expect the US Food and Drug Administration to make a decision by the end of March to clear the market return of the company's recalled drug, Tysabri. ...
Elan Tysabri Could Hit $1.8B Sales - NCB Jan 11, 2006
New Ratings 1305 GMT [Dow Jones] NCB Stockbrokers says $1.6B in peak sales for suspended MS drug Tysabri are factored into the share price of over $14. ...
Roller-coaster ride for Elan shareholders on back of Tysabri Jan 3, 2006
Biotechnology Ireland, The year had started out as a promising one for Elan, with high hopes its multiple sclerosis treatment Tysabri would prove to be a blockbuster and transform ...
Biomed Rounds: Will Biogen’s Tysabri make a comeback in 2006? Dec 27, 2005
Boston Mass High Tech, ...disease were linked to the compound. The evidence that Tysabri was the direct cause is scant. Subsequent tests by Biogen Idec have ...
Ex-Biogen counsel to pay $3m Jan 13, 2006
Boston Globe, ...general counsel Thomas J. Bucknum to settle charges that he dumped stock after learning of problems with Tysabri, a multiple sclerosis drug that the Cambridge ...
Ex-Biogen chief pays $3m in insider dealing case Jan 13, 2006
Unison.ie, A FORMER executive with Biogen, which is Elan's partner in the marketing of Tysabri, has settled an insider dealing case with the US authorities and agreed to ...
Approval to restart Phase IIa trial in MS patients Jan 12, 2006
Biotech Intelligence (press release), ...mechanism of action in blocking VLA-4 is different to other drugs in development that target VLA-4 (including the monoclonal antibody Tysabri®) and represents ...
Ex-Biogen Exec Settles Insider Trading Claims Jan 13, 2006
Los Angeles Times, ...shares of Biogen stock the same day the firm says it learned of patient illnesses that led to the withdrawal of its multiple sclerosis drug Tysabri from the ...
Biogen ex-exec to settle charges Jan 13, 2006
News & Observer, ...of Biogen Idec stock the same day the company says it learned of patient illnesses that led to the withdrawal of its multiple sclerosis drug Tysabri from the ...
UPDATE 1-Ex-Biogen exec to pay $3 mln for insider trading Jan 12, 2006
Reuters The case stems from Biogen's suspension last February of the multiple sclerosis drug Tysabri after the company along with development partner Elan Corp. ...
Elan downgraded to "add" Jan 13, 2006
New Ratings Elan's share price has appreciated over the past six weeks on market optimism regarding Tysabri being approved by the FDA and the drug returning to the market ...
Biogen Idex expects ruling by March on drug relaunch Jan 11, 2006
Boston Business Journal, Biogen Idec Inc. expects federal regulators to rule by March about relaunching multiple sclerosis drug Tysabri in the marketplace. ...
Loving Elan's Latest Comeback Jan 4, 2006
Forbes Elan lost nearly 90% of its value early in 2005 when it pulled multiple sclerosis treatment Tysabri off of the market in February after the deaths of two ...
Ex-Biogen counsel agrees to SEC settlement Jan 12, 2006
Raleigh Triangle Business Journal, BIIB) last February for a $1.9 million gain, with the SEC saying he did so after learning two patients taking its multiple sclerosis drug Tysabri had developed ...
SEC Files Settled Insider Trading Action Against Former General ... Jan 12, 2006
PharmaLive.com (press release), Specifically, Bucknum learned that a patient participating in a clinical trial of Biogen's multiple sclerosis drug, Tysabri, had been diagnosed with ...
Ex-Biogen Exec. Settles Insider Trade Case Jan 12, 2006
Herald News Daily, April, the company said in a regulatory filing that the SEC was formally investigating possible securities laws violations related to Tysabri‘s withdrawal. ...
Boston booked record 108 conventions last year Jan 11, 2006
Boston Globe, ...said its Tysabri multiple sclerosis medicine, suspended in 2005 after being linked to an often fatal nervous system disease, may return to the market this year ...
Medicare focus as pharma firms meet Jan 7, 2006
MarketWatch ...topics will include the simmering litigation that has surrounded Big Pharma, the expected market return of the recalled biotech drug Tysabri, and continued ...
Ex-Biogen Idec executive settles insider trading case for $3 ... Jan 12, 2006
Eyewitness News, ...move came amid a regulatory inquiry into his sale of Biogen stock the same day the company says it learned of safety problems with its MS drug, Tysabri (ty-SAH ...
MARKET COMMENT: Dublin Stocks End Flat, Elan +3.1% Jan 12, 2006
New Ratings Elan +3.1% as investors await more news on the FDA's review of MS drug Tysabri. Financials mixed: Anglo Irish Bank -1.4%, Irish Life & Permanent +1.3%. ...
Biogen general counsel to pay $3m to settle SEC investigation Jan 12, 2006
Boston Globe, 18, the day company executives learned that two patients in a long term trial of its multiple sclerosis drug Tysabri had a rare disease. On Feb. ...
IFG climbs 16pc on broker reports Jan 13, 2006
Unison.ie, It was followed by drug manufacturer Elan which gained 13pc. Elan shares gained after an investor conference at its Tysabri research partner Biogen. ...
Back in hot seat with quiver full of gold-tipped arrows Jan 14, 2006
Unison.ie, They were Fyffes and DCC. Ben also picked Elan, which of course lost half of its value in 2005 as a result of the Tysabri affair.
Sereno initiated with "underweight" Jan 4, 2006
New Ratings A recent physician survey indicates that Rebif may witness marginal market share losses due to Tysabri's return to the market, the analyst says.
Pfizer Buying Into Perlegen's Pharmacogenomics Platform Dec 27, 2005
BioWorld Online (subscription), One drug that theoretically could benefit from pharmacogenomics is the multiple sclerosis drug Tysabri, developed by Dublin, Ireland-based Elan Corp. ...
Today in the press Dec 30, 2005
RTE.ie, Roller-coaster ride for Elan shareholders on back of Tysabri - Shareholders in Elan are getting used to a roller-coaster ride when it comes to the performance ...
Irish stock exchange on course to be European favourite Dec 31, 2005
The Sunday Times, The main laggards were: Elan, where concerns over Tysabri affected investor sentiment; Waterford Wedgwood, which was dogged by weak sales in America; and Iona ...
Elan share price may drift on a lack of news Dec 29, 2005
Unison.ie, ..."We expect some weakening in the share price through January, unless there is substantive newsflow on Tysabri's progress thorough the regulatory process," the ...
Merrill Lynch issues 'sell' rating on Elan Dec 24, 2005
Unison.ie, Merrill believes that the current share price is discounting sales for Elan's critical multiple sclerosis drug, Tysabri, of more than $1.5bn, which the ...
The gleam of growth in a metals distributor Dec 27, 2005
MSN Money The analysts agree with me that Tysabri (a new treatment for multiple sclerosis) is likely to be re-approved by the US Food and Drug Administration in March ...
Sharp fall in Elan as Merrill says 'sell' Dec 20, 2005
Unison.ie, Merrill said in a research note that Elan's current share price reflected a more optimistic scenario than was warranted for its Tysabri multiple sclerosis drug ...
Elan "sell" Dec 20, 2005
New Ratings ...note published this morning, the analysts mention that the company’s share price reflects a more-optimistic-than-warranted scenario for Tysabri, the multiple ...
Top Five Healthcare Events of 2005, According to Decision ... Dec 28, 2005
PR Newswire (press release), Reference Pricing, BiDil, Tysabri, Medicare Part D, and Vioxx All Impacted the Healthcare Industry in 2005 WALTHAM, Mass., Dec. ...
UK Stocks Climb, Paced by RBS, HBOS, P&O, British Airways Jan 11, 2006
Bloomberg ...in Dublin. US partner Biogen Idec Inc. said the Tysabri multiple-sclerosis medicine may return to the market this year. The drug ...
Elan Momentum Seen Easing Over Holidays Dec 19, 2005
New Ratings The FDA Advisory Committee for peripheral and central nervous system drugs will possibly review MS drug Tysabri on March 7 and 8, according to Elan's partner ...
Genentech/Biogen Idec: wearing the drug marketing suit well? Jan 12, 2006
Pharmaceutical Business Review While Biogen Idec will not relish more bad press after beginning to get back on its feet following troubles with multiple sclerosis drug Tysabri last year ...
11am Markets Update Jan 11, 2006
RTE.ie, Dublin's ISEQ had gained 50 points to stand at 7,473 with shares in Elan up 34 cent to €12.20 after a positive outlook for the MS drug Tysabri from its ...
Elan drives market advance Jan 11, 2006
IrishExaminer.com, Elsewhere, Elan surged on the back of Biogen Idec’s expectation that the US FDA will have reached its decision on Tysabri by the end of March. ...
Deal-making reveals shifting economy Jan 1, 2006
Eagle Tribune, The firm's shares plunged more than 42 percent in February the day it withdrew its multiple sclerosis drug Tysabri because of patient deaths. ...
Elan "buy" Dec 28, 2005
New Ratings In a research note published this morning, the analyst mentions that the decision on the return of Tysabri to the US market is expected during late March 2006 ...
ISEQ ends 2005 on a record high Dec 30, 2005
RTE.ie, Its performance has once again been hit by the problems with Elan, which saw its shares plunge in February and March after the withdrawal of its MS drug Tysabri ...
StreetNotes: A Daily Roundup of Street Research Jan 5, 2006
TheStreet.com Biogen Idec downgraded at CSFB: CSFB said it is downgrading BIIB to Underperform from Neutral on belief that "Tysabri return" trade had run its course and ...
Biotech Racks Up Another Impressive Quarter to Close Year in ... Jan 3, 2006
PR Newswire (press release), ...news that had regulators granted priority review status to its, along with partner Elan Corp., application to bring the withdrawn Tysabri multiple sclerosis ...
Nutra Pharma Reports Discovery of New Gene Involved in Multiple ... Jan 3, 2006
PR Newswire (press release), A fifth drug, Tysabri, was voluntarily pulled from the marketplace in February by the drug's manufacturers, Biogen-Idec (Nasdaq: BIIB) and Elan (NYSE: ELN). ...
Thursday December 29th 2005 Dec 29, 2005
Unison.ie, December. The shares are likely to be hampered by a lack of newsflow until the regulators in the US decide to approve its Tysabri drug. ...
ISEQ set to reach record level Dec 29, 2005
IrishExaminer.com, Its performance has once again been hit by the problems with Elan, which saw its shares plunge in February after the withdrawal of its drug Tysabri. ...
Top Five Healthcare Events of 2005, According to Decision ... Dec 28, 2005
PharmaLive.com (press release), ...in. approval based on its performance in a particular race. 3. Biogen Idec and Elan withdrawal of Tysabri for the treatment of. 2. Medicare ...
Do as these directors do Dec 17, 2005
Irish Independent, Then a few weeks later the company revealed unexpected side-effects which forced it to pull its Tysabri drug from the market and the shares lost over two ...
Elan plunges 462 places on BusinessWeek's Global 1200 company ... Dec 19, 2005
FinFacts Ireland, Elan shares plummeted 68% on one dark day in February after it pulled multiple sclerosis treatment Tysabri, a drug implicated in three deaths, from the US ...
Top five healthcare events of 2005, according to Decision ... Dec 29, 2005
Dominican Today, 3. Biogen Idec and Elan withdrawal of Tysabri for the treatment of multiple sclerosis – hailed by physicians and industry analysts as a promising new ...
Resources and commodities provided the most cheer Dec 27, 2005
Unison.ie, ...have been the biggest of the year's losers but it certainly suffered the sharpest fall back in February when the Multiple Sclerosis drug Tysabri was withdrawn ...
|
|
|
